Drug Delivery Market

According to Stratistics MRC, the Global Drug Delivery Market is accounted for $20.2 billion in 2023 and is expected to reach $35.5 billion by 2030 growing at a CAGR of 8.4% during the forecast period. Drug delivery refers to the process of administering pharmaceutical substances, such as drugs or therapeutic agents, to the human body in a controlled and targeted manner. It is essential for improving the therapeutic impact of pharmaceuticals, reducing side effects, and enhancing patient compliance. It plays a critical role in advancing medical treatments and the overall quality of patient care.

According to the American Heart Association, 101.5 million stroke cases worldwide in 2019. Ischemic stroke cases were 77.2 million, intracerebral hemorrhage cases were 20.7 million, and subarachnoid hemorrhage cases were 8.4 million.

Market Dynamics: 

Driver: 

Rise in precision medicine

Precision medicine tailors medical treatments, including drug therapies, to an individual's unique genetic, genomic, and physiological characteristics. This approach demands precise drug delivery systems that can target specific molecular pathways or cells with high accuracy. As a result, drug delivery technologies have evolved to accommodate the requirements of personalized medicine, enabling the administration of precise dosages at specific times and locations in the body. This ensures that the right treatment reaches the right patient, maximizing therapeutic effectiveness while minimizing side effects. 

Restraint:

High development costs

Researching and developing new drug delivery technologies, from formulation enhancements to advanced delivery systems, can be a financial burden. These costs encompass pre-clinical testing, clinical trials, regulatory approvals, and manufacturing processes. The complexity and innovation required for cutting-edge drug delivery systems further drive up expenses. Moreover, these high development costs can deter smaller companies from entering the market and may slow down the pace of innovation. It necessitates substantial financial investments and makes it challenging for companies to bring cost-effective solutions to market, ultimately affecting the accessibility and affordability of advanced drug delivery methods.

Opportunity:

Growth of telemedicine and remote monitoring

The growth of telemedicine and remote patient monitoring presents a substantial opportunity for the drug delivery market. Telehealth's expanding popularity allows patients to access healthcare services from the comfort of their homes, reducing the need for in-person clinic visits. This shift towards remote care creates a demand for innovative drug delivery systems that enable patients to self-administer medications effectively and safely under remote medical supervision. Whether it's managing chronic conditions or delivering critical therapies, these remote drug delivery solutions can improve patient compliance, treatment outcomes, and overall healthcare efficiency. As telemedicine continues to gain momentum, the drug delivery market has the potential to develop and offer new, patient-centric technologies that align with the evolving landscape of healthcare delivery, ultimately enhancing the accessibility and effectiveness of drug treatments.

Threat:

Cybersecurity risks

Cybersecurity risks represent a growing threat to the drug delivery market. As drug delivery systems become increasingly interconnected and reliant on digital technologies, they become susceptible to cyber attacks. Malicious actors could potentially compromise the security and functionality of these systems, endangering patient safety and the integrity of drug administration. Such attacks may lead to incorrect dosing, unauthorized access to patient data, or system failures. Ensuring the cybersecurity of these devices is imperative, as breaches can have severe consequences, eroding patient trust and industry reputation.

Covid-19 Impact

The outbreak of COVID-19 has disrupted workflows in the healthcare sector around the world due to factors such as reduced hospital admissions, disruptions in the supply chain, temporary halts in manufacturing, and others across the globe. The disease has forced a number of industries to temporarily shut their doors, including several sub-domains of health care. The global pharmaceutical drug delivery market was moderately impacted during the pandemic due to disruptions in the supply of pharmaceutical products. However, with the launch of COVID-19 vaccines and mass vaccination drives, there was a significant acceleration in manufacturers’ production of injectable drug delivery systems to meet global medical needs. The market in the post-pandemic period will grow significantly due to increased hospital visits and the launch of advanced drug delivery systems, among others. 

The Implantable Drug Delivery segment is expected to be the largest during the forecast period

The Implantable Drug Delivery segment is estimated to hold the largest share. Implantable drug delivery is a specialized segment of the drug delivery market that involves the use of medical devices designed to deliver pharmaceutical agents directly into the body for controlled and sustained release. These devices, often implanted under the skin or within specific bodily tissues, can administer drugs over extended periods, reducing the need for frequent dosing. Implantable drug delivery systems are used in various medical applications, including the treatment of chronic conditions such as diabetes and pain management, offering patients convenience and improved therapeutic outcomes while minimizing potential side effects. This segment represents an innovative approach to enhancing drug efficacy and patient compliance. 

The Cardiovascular Diseases segment is expected to have the highest CAGR during the forecast period

The Cardiovascular Diseases segment is anticipated to have lucrative growth during the forecast period. Cardiovascular diseases (CVD) represent a significant and multifaceted segment within the drug delivery market. This sector is dedicated to developing innovative drug delivery systems and therapies aimed at preventing, managing, and treating conditions such as hypertension, coronary artery disease, heart failure, and stroke. Drug delivery technologies for CVD encompass a wide range of solutions, including controlled-release formulations, stents coated with medications to prevent artery blockage, and novel delivery methods for anticoagulants and antiplatelet agents. These advancements improve the efficacy of medications, enhance patient compliance, and reduce the risk of adverse cardiovascular events. Moreover, with CVD being a leading cause of mortality worldwide, the cardiovascular drug delivery market plays a pivotal role in mitigating this public health crisis by providing solutions that contribute to better outcomes and overall cardiovascular health.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The rising incidence of cancer and growing public knowledge of cancer treatments are the main causes of this region's market expansion. With a vast population, the Asia-Pacific region has experienced an increase in cancer prevalence in recent years as a result of changing lifestyles, environmental factors, and aging populations. As a result, there are an increasing number of patients receiving treatment, which raises the need for the distribution of pharmaceutical drugs. Moreover, due to the increase in disposable income as well as the lucrative potential for major participants in the market, Asia-Pacific is expected to develop at the highest rate during the forecast period. Furthermore, manufacturers in India are increasing their production capacities to meet the rising demand for syringes, thereby fostering overall market growth across the region. 

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. This is attributed to several factors, including the increased occurrence of chronic illnesses including diabetes, cancer, and respiratory allergies; increased patient adherence to novel drug delivery technology; and the concentration of notable individuals in this area. The market is expanding due to the presence of many significant players, including Novartis AG, Pfizer Inc., F. Hoffmann La-Roche Ltd., and Merck and Co., Inc., in the area. Moreover, the need for pharmaceutical drug delivery solutions in North America is growing rapidly due to the biopharmaceutical industry's development of numerous novel medications that can cure a range of non-communicable disorders.

Key players in the market

Some of the key players in the Drug Delivery Market include Abbott, Bayer, AstraZeneca, Sanofi, GlaxoSmithKline, La Roche, Johnson & Johnson, Novartis AG, Merck, Pfizer, Antares Pharma, GSK, Accord Healthcare, Becton Dickinson and Co, Boston Scientific Corp, Baxter International Inc, Kindeva Drug Delivery LP, Gerresheimer AG, Sever Pharma Solutions and Boehringer Ingelheim International.

Key Developments:

In December 2022, Johnson & Johnson announced the launch of its ACUITY™ MRI SureScan™ pacemaker. This pacemaker is the first and only MRI-conditional pacemaker that is also compatible with Johnson & Johnson's ACUITY™ MRI SureScan™ defibrillator.

In November 2022, Sorin Group announced the launch of its Evia™ leadless pacemaker. This pacemaker is a small, wireless device that is implanted directly into the heart without the need for leads.

In October 2022, Arena Pharmaceuticals announced the approval of its drug, ravulizumab, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ravulizumab is a long-acting, subcutaneously administered C5 complement inhibitor that provides sustained protection from hemolysis in patients with PNH.

In September 2022, Alnylam Pharmaceuticals announced the approval of its drug, vutrisiran, for the treatment of hereditary transthyretin amyloidosis (ATTR amyloidosis). Vutrisiran is a subcutaneously administered RNA interference (RNAi) therapy that targets the production of TTR protein.

In August 2022, Sanofi announced the approval of its drug, Dupixent, for the treatment of atopic dermatitis in adults and children aged 6 years and older. Dupixent is a human monoclonal antibody that targets the IL-4 and IL-13 cytokines.

Types Covered:
• Injectable Drug Delivery 
• Transdermal Drug Delivery 
• Oral Drug Delivery 
• Topical Drug Delivery 
• Transmucosal Drug Delivery 
• Implantable Drug Delivery 
• Ocular Drug Delivery 
• Other Types 

Device Types Covered:
• Advanced
• Conventional

Distribution Channels Covered:
• Retail Pharmacies
• Hospital Pharmacies 
• Online Pharmacies 
• Other Distribution Channels 

Applications Covered:
• Oncology
• Cardiovascular Diseases
• Diabetes
• Central Nervous System Disorders
• Respiratory Diseases
• Other Applications

End Users Covered:
• Home Care Settings 
• Hospitals and Clinics 
• Ambulatory Surgical Centers 
• Other End Users 

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan        
o China        
o India        
o Australia  
o New Zealand
o South Korea
o Rest of Asia Pacific    
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa 
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings: 
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances